Loss of Hepatocyte FOXA3 Improves MASH and Atherosclerosis in Hyperlipidemic Ldlr-Deficient Mice
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27031468 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Hui Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and the Translational Cardiovascular Research Center, University of Arizona College of Medicine-Phoenix, Phoenix, AZ …. Hauptthemen laut MEDLINE: Atherosclerosis, Receptors, LDL, Hepatocytes, Hyperlipidemias. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIDDK NIH HHS, NIAAA NIH HHS.
Abstract (Originalsprache)
Forkhead box protein A3 (FOXA3), also known as hepatocyte nuclear factor 3g (HNF3g), is a member of the FOX family of transcription factors and regulates lipid and glucose metabolism and liver regeneration. Hepatic FOXA3 is reduced in obesity and patients with metabolic dysfunction-associated steatohepatitis (MASH). So far, it remains unknown whether hepatic FOXA3 is essential for regulating lipid metabolism or metabolic dysfunction-associated liver disease (MASLD). In this study, we first investigated whether genetic inactivation of hepatocyte Foxa3 affected the development of MASLD/MASH in C57BL/6 mice and then explored whether loss of hepatocyte Foxa3 regulated atherosclerosis development in Ldlr-deficient mice. Inactivation of Foxa3 in hepatocytes did not affect the development of Western diet-induced MASLD/MASH in C57BL/6 mice but attenuated MASH development in Western diet-fed Ldlr-deficient mice. Moreover, genetic loss of hepatocyte Foxa3 ameliorated hyperlipidemia and atherosclerosis in Ldlr-deficient mice. In Ldlr-deficient mice, loss of hepatocyte Foxa3 resulted in reduced expression of lipogenic, pro-inflammatory, or fibrogenic genes in the liver and reduced cholic acid levels in plasma and bile. Thus, hepatocyte FOXA3 loss confers protection against the development of MASH and atherosclerosis in hyperlipidemic Ldlr-deficient mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and the Translational Cardiovascular Research Center, University of Arizona College of Medicine-Phoenix, Phoenix, AZ 85004, USA.
- School of Biomedical Sciences, Kent State University, Kent, OH 44272, USA.
- Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA.
ORCID-Profile: Liya Yin
Förderung
- NIH HHS
- NIDDK NIH HHS
- NIAAA NIH HHS
- NIH
Zitieren
APA
Wang, H., Hu, S., Wang, J., Gopoju, R., Lin, L., Gunawardana, L., Wang, X., Yin, L., & Zhang, Y. (2026). Loss of Hepatocyte FOXA3 Improves MASH and Atherosclerosis in Hyperlipidemic Ldlr-Deficient Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031468
Vancouver
Wang H, Hu S, Wang J, Gopoju R, Lin L, Gunawardana L, et al. Loss of Hepatocyte FOXA3 Improves MASH and Atherosclerosis in Hyperlipidemic Ldlr-Deficient Mice. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031468
BibTeX
@article{Wang2026,
author = {Wang, Hui and Hu, Shuwei and Wang, Jiayou and Gopoju, Raja and Lin, Li and Gunawardana, Lakshitha and Wang, Xinwen and Yin, Liya and Zhang, Yanqiao},
title = {Loss of Hepatocyte FOXA3 Improves MASH and Atherosclerosis in Hyperlipidemic Ldlr-Deficient Mice},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27031468}
}
EUVIMED